Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Courjon

Showing results (181-190 of 194) with videos related to

Pageof 20
Sort By:
International Journal of Antimicrobial Agents|December 27, 2024
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949]Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, et al.
International Journal of Antimicrobial Agents|March 25, 2020
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialPhilippe Gautret, Jean-Christophe Lagier, Philippe Parola, et al.
International Journal of Molecular Sciences|February 25, 2023
Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load SpecimensMarius Ilié, Jonathan Benzaquen, Véronique Hofman, et al.
Nature Microbiology|January 12, 2021
Escherichia coli Rho GTPase-activating toxin CNF1 mediates NLRP3 inflammasome activation via p21-activated kinases-1/2 during bacteraemia in miceOcéane Dufies, Anne Doye, Johan Courjon, et al.
Blood Advances|March 8, 2021
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severityJohan Courjon, Océane Dufies, Alexandre Robert, et al.
International Journal of Antimicrobial Agents|August 11, 2019
French national cohort of first use of dalbavancin: A high proportion of off-label useAurélien Dinh, Clara Duran, Patricia Pavese, et al.
JAMA Dermatology|November 25, 2020
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 PandemicThomas Hubiche, Nathalie Cardot-Leccia, Florence Le Duff, et al.
The Journal of Experimental Medicine|August 30, 2024
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activationAnne Doye, Paul Chaintreuil, Chantal Lagresle-Peyrou, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National CohortAva Diarra, Maxime Degrendel, Isabelle Eberl, et al.
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
Pageof 20

Showing results (181-190 of 194) with videos related to

Sort By:
Pageof 20
International Journal of Antimicrobial Agents|December 27, 2024
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949]Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, et al.
International Journal of Antimicrobial Agents|March 25, 2020
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialPhilippe Gautret, Jean-Christophe Lagier, Philippe Parola, et al.
International Journal of Molecular Sciences|February 25, 2023
Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load SpecimensMarius Ilié, Jonathan Benzaquen, Véronique Hofman, et al.
Nature Microbiology|January 12, 2021
Escherichia coli Rho GTPase-activating toxin CNF1 mediates NLRP3 inflammasome activation via p21-activated kinases-1/2 during bacteraemia in miceOcéane Dufies, Anne Doye, Johan Courjon, et al.
Blood Advances|March 8, 2021
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severityJohan Courjon, Océane Dufies, Alexandre Robert, et al.
International Journal of Antimicrobial Agents|August 11, 2019
French national cohort of first use of dalbavancin: A high proportion of off-label useAurélien Dinh, Clara Duran, Patricia Pavese, et al.
JAMA Dermatology|November 25, 2020
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 PandemicThomas Hubiche, Nathalie Cardot-Leccia, Florence Le Duff, et al.
The Journal of Experimental Medicine|August 30, 2024
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activationAnne Doye, Paul Chaintreuil, Chantal Lagresle-Peyrou, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National CohortAva Diarra, Maxime Degrendel, Isabelle Eberl, et al.
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
Pageof 20